Linked Life Data

19004633

Source:http://linkedlifedata.com/resource/pubmed/id/19004633

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-3-3
pubmed:abstractText
New technologies are expensive. The health care budget cannot expand indefinitely so if new treatments are introduced they may have to displace other treatments, or prevent other new treatments coming into practice. This is not simply a money saving exercise; it is accepted that new high technology treatments may cost more to implement but they must be worth the money spent in comparison with other treatments. Therefore cardiothoracic surgeons must first demonstrate that our treatments are effective. Then we need evidence of cost effectiveness in comparison with other therapies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1873-734X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
474-8; discussion 478-9
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Are randomised trials needed in the era of rapidly evolving technologies?
pubmed:affiliation
Clinical Operational Research Unit, Department of Mathematics, UCL, London, United Kingdom. tom.treasure@gmail.com
pubmed:publicationType
Journal Article, Review